EGFR and lung adenocarcinoma: Similarly, in a retrospective study conducted by Hu et al., 231 lung adenocarcinoma patients with oligometastatic lesions (1 organ, ≤5 lesions) and EGFR mutation were divided into 2 groups, 1 receiving first‐generation EGFR TKI monotherapy (n = 88) and the other local consolidative therapy (LCT) plus TKI before progression (n = 143).